Comparative Pharmacology
Head-to-head clinical analysis: QUINAGLUTE versus QUINALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINAGLUTE versus QUINALAN.
QUINAGLUTE vs QUINALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; binds to sodium channels and inhibits the fast inward sodium current, slowing phase 0 depolarization and prolonging the action potential duration. Also exhibits anticholinergic and negative inotropic effects.
Quinidine (the active ingredient in Quinalan) is a class Ia antiarrhythmic agent that binds to and blocks voltage-gated sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period. It also has vagolytic effects and blocks potassium channels.
324-648 mg orally every 8-12 hours; extended-release formulation (quinidine gluconate).
10 mg orally once daily, may increase to 20 mg after 2 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours in adults with normal renal function. In hepatic impairment, half-life may increase to 12-24 hours; in severe renal impairment (CrCl <10 mL/min), half-life may exceed 24 hours.
Terminal half-life: 12 hours (range 10-14) in normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of total clearance. Biliary/fecal excretion contributes about 20-30%. Acidic urine increases renal clearance.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% other.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)